Protalix BioTherapeutics Reaches New 12-Month Low at $2.35 (PLX)
Protalix BioTherapeutics (NYSE:PLX) shares reached a new 52-week low on Wednesday , Analyst Ratings Net reports. The stock traded as low as $2.35 and last traded at $2.43, with a volume of 627,535 shares trading hands. The stock had previously closed at $2.65.
Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday, August 11th. They now have a $3.50 price target on the stock, down previously from $4.25.
The stock has a 50-day moving average of $3.20 and a 200-day moving average of $4.04. The company’s market cap is $232.1 million.
Protalix BioTherapeutics (NYSE:PLX) last posted its quarterly earnings results on Friday, August 15th. The company reported ($0.07) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.07). Analysts expect that Protalix BioTherapeutics will post $-0.21 EPS for the current fiscal year.
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.